医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China

2021年05月18日 PM12:19
このエントリーをはてなブックマークに追加


 

BEIJING

InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that China National Medical Products Administration has approved the Phase I clinical trial of InnoCare’s novel TYK2 (Tyrosine Kinase 2) inhibitor, which becomes the company’s fifth innovative drug to enter the clinical phase.

InnoCare developed oral ICP-332 with global IP rights. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway, playing an important role in the pathogenesis of inflammatory diseases. Currently no selective TYK2 inhibitor has entered the market globally.

ICP-332 is designed to be a potent and selective TYK2 inhibitor with 400 folds of selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors. ICP-332 will be used to treat autoimmune diseases such as psoriasis and atopic dermatitis.

Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare said, “We are committed to our core value of ‘Science drives innovation for the benefit of patients’. The approval of ICP-332 clinical trial enriches our drug pipeline and it is the fifth innovative drug to enter the clinical phase, further strengthening our pipeline in autoimmune diseases. We will push forward the clinical trials to benefit patients.”

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517006023/en/

CONTACT

Media

Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investor

86-10-66609999

ir@innocarepharma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆